Literature DB >> 3578259

Porphyria cutanea tarda associated with the acquired immune deficiency syndrome.

P S Wissel, P Sordillo, K E Anderson, S Sassa, R L Savillo, A Kappas.   

Abstract

Three male subjects with cutaneous symptoms and biochemical signs typical of porphyria cutanea tarda (PCT) developed acquired immune deficiency syndrome (AIDS). All three were in a classic high risk group for the latter disease and developed a typical progressive illness. Two patients succumbed to opportunistic infections; the third is alive but critically ill. The symptomatic prodrome of AIDS developed concurrently with or followed the onset of symptoms of PCT in all three individuals. PCT and AIDS are both uncommon disorders; their association in three patients is thus of inherent clinical interest. If this association is not coincidental, it raises the possibility that the occurrence of photosensitivity, skin lesions, and evidence of biochemical changes characteristic of PCT may, in certain patients at risk for AIDS, presage the subsequent full clinical expression of the latter disease.

Entities:  

Mesh:

Year:  1987        PMID: 3578259     DOI: 10.1002/ajh.2830250112

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  10 in total

1.  Porphyria cutanea tarda and HIV infection: effect of zidovudine treatment on a patient.

Authors:  S Gafà; A Zannini; C Gabrielli
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

2.  Porphyria cutanea tarda and human immunodeficiency virus: two new cases.

Authors:  F Lacoma; M Yebra; F Albarrán; M Moya
Journal:  Postgrad Med J       Date:  1989-07       Impact factor: 2.401

Review 3.  [Hepatic porphyrias and alcohol].

Authors:  M O Doss; A Kühnel; U Gross; I Sieg
Journal:  Med Klin (Munich)       Date:  1999-06-15

Review 4.  Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.

Authors:  Vaithamanithi-Mudumbai Sadagopa Ramanujam; Karl Elmo Anderson
Journal:  Curr Protoc Hum Genet       Date:  2015-07-01

5.  Heme inhibits human immunodeficiency virus 1 replication in cell cultures and enhances the antiviral effect of zidovudine.

Authors:  R D Levere; Y F Gong; A Kappas; D J Bucher; G P Wormser; N G Abraham
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

6.  Highly active antiretroviral therapy leading to resolution of porphyria cutanea tarda in a patient with AIDS and hepatitis C.

Authors:  J D Rich; E Mylonakis; R Nossa; R M Chapnick
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

7.  Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency.

Authors:  Norman G Egger; Douglas E Goeger; Deborah A Payne; Emil P Miskovsky; Steven A Weinman; Karl E Anderson
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

8.  Porphyria cutanea tarda in association with the human immunodeficiency virus infection.

Authors:  E L Ong; M E Ellis; D McDowell; M Gebril; C Weinkove; R Ead
Journal:  Postgrad Med J       Date:  1988-12       Impact factor: 2.401

9.  Porphyria cutanea tarda in a human immunodeficiency virus-infected patient: A rare scenario in India.

Authors:  Ramesh M Bhat; Malcolm Pinto; S Dandakeri; Srinath M Kambil
Journal:  Indian J Sex Transm Dis AIDS       Date:  2014-01

10.  Human Immunodeficiency Virus Associated Sporadic Nonfamilial Porphyria Cutanea Tarda.

Authors:  Sibashish Kamal Guha; Debabrata Bandyopadhyay; Abanti Saha; Niharika Ranjan Lal
Journal:  Indian J Dermatol       Date:  2016 May-Jun       Impact factor: 1.494

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.